ANA

Antinuclear Antibodies

Inmunidad e inflamación

Última revisión: 7 de abril de 2026. Enfoque de fuentes: contexto estándar de interpretación de laboratorio, material médico de referencia y orientación clínica o de salud pública cuando corresponde.

¿Qué es Antinuclear Antibodies?

Antinuclear antibodies (ANA) are autoantibodies directed against various components of the cell nucleus, including DNA, histones, nucleolar proteins, centromeres, and other nuclear antigens. The ANA test is the most widely used screening test for systemic autoimmune diseases, particularly systemic lupus erythematosus (SLE). The standard testing method is indirect immunofluorescence (IIF) on HEp-2 cells, which allows visualization of the staining pattern—a critical piece of diagnostic information. Results are reported as a titer (e.g., 1:80, 1:160, 1:320) reflecting the highest dilution at which fluorescence is still detected, along with the pattern of nuclear staining.

The ANA staining pattern provides clues to the specific autoantibodies present and the likely diagnosis: homogeneous pattern suggests anti-dsDNA or anti-histone antibodies (associated with SLE and drug-induced lupus); speckled pattern suggests anti-Smith, anti-RNP, anti-SSA/Ro, or anti-SSB/La antibodies (associated with SLE, mixed connective tissue disease, or Sjogren's syndrome); centromere pattern is highly specific for limited cutaneous systemic sclerosis (CREST syndrome); and nucleolar pattern suggests anti-RNA polymerase or anti-Scl-70 antibodies (associated with systemic sclerosis). A positive ANA alone does not diagnose any disease—it must be interpreted in clinical context.

Por qué importa

The ANA test is the gateway screening test for systemic autoimmune diseases. A negative ANA at 1:80 or higher effectively rules out SLE (sensitivity >95%). However, a positive ANA is found in many conditions beyond autoimmune disease—up to 15–20% of healthy individuals have a low-titer positive ANA, and prevalence increases with age, particularly in women. The clinical value of an ANA test depends entirely on the pre-test probability: ordering it in a patient with joint pain, rash, serositis, and cytopenias is highly informative, while ordering it as a nonspecific "screening" test in patients with vague fatigue often leads to unnecessary anxiety and further testing.

Rangos de referencia normales

GrupoRangoUnidad
Negative<1:40titer
Low positive (often clinically insignificant)1:40–1:80titer
Moderate positive1:160–1:320titer
High positive (more likely clinically significant)≥1:640titer

Los rangos de referencia pueden variar entre laboratorios. Compara siempre tus resultados con los rangos proporcionados por tu laboratorio.

Qué significan los niveles altos de ANA

Causas comunes

  • Systemic lupus erythematosus (SLE)—positive in >95% of cases
  • Drug-induced lupus (hydralazine, procainamide, isoniazid)
  • Sjogren's syndrome
  • Systemic sclerosis (scleroderma)
  • Mixed connective tissue disease
  • Polymyositis/dermatomyositis
  • Autoimmune hepatitis
  • Rheumatoid arthritis (in some patients)
  • Healthy individuals (up to 15–20%, usually low titer)
  • Older age (higher prevalence of low-titer positive ANA)
  • Infections (EBV, hepatitis C) and certain medications

Posibles síntomas

  • A positive ANA itself does not cause symptoms
  • Symptoms depend on the underlying condition—may include joint pain, skin rashes, fatigue, mouth ulcers, hair loss, Raynaud's phenomenon, dry eyes/mouth, or muscle weakness

Qué hacer: A positive ANA should prompt evaluation of the clinical picture. If autoimmune disease is suspected, order specific antibodies based on the ANA pattern: anti-dsDNA and anti-Smith for SLE, anti-SSA/SSB for Sjogren's, anti-centromere and anti-Scl-70 for systemic sclerosis, anti-Jo-1 for myositis. Check complement levels (C3, C4), CBC, urinalysis, and inflammatory markers. A low-titer ANA (≤1:80) in the absence of suggestive symptoms generally does not warrant further testing. Refer to rheumatology when clinical features align with a systemic autoimmune disease.

Qué significan los niveles bajos de ANA

Causas comunes

  • A negative ANA is the normal result
  • ANA-negative lupus occurs rarely (<5% of SLE cases)—these patients may have anti-Ro/SSA antibodies detectable by other methods

Posibles síntomas

  • No symptoms from a negative ANA

Qué hacer: A negative ANA is reassuring and effectively rules out SLE in most cases. If clinical suspicion for SLE or Sjogren's remains high despite a negative ANA, consider testing for anti-Ro/SSA antibodies specifically, as these can be present in ANA-negative lupus. No follow-up testing is needed for a negative ANA in the absence of clinical concern.

¿Cuándo se recomienda la prueba de ANA?

  • When systemic lupus erythematosus is clinically suspected (malar rash, photosensitivity, joint pain, serositis, cytopenias)
  • When Sjogren's syndrome is suspected (dry eyes, dry mouth, parotid swelling)
  • When systemic sclerosis is suspected (Raynaud's, skin thickening, digital ulcers)
  • As part of the workup for unexplained inflammatory arthritis
  • When autoimmune hepatitis is suspected

Preguntas frecuentes

Not necessarily. A positive ANA is found in many conditions and in up to 15–20% of healthy people, especially women and older adults. The ANA test is very sensitive for lupus (>95% of lupus patients are ANA-positive) but not very specific. A diagnosis of lupus requires a combination of clinical features (rash, joint pain, kidney disease, blood count abnormalities) plus supportive lab findings. Think of the ANA as an initial screening test that, when positive, prompts more specific testing.
The immunofluorescence pattern on HEp-2 cells reflects which nuclear components the antibodies target. A homogeneous pattern is commonly associated with lupus (anti-dsDNA, anti-histone). A speckled pattern can be seen in many autoimmune conditions (lupus, Sjogren's, MCTD). A centromere pattern is highly associated with limited systemic sclerosis (CREST). A nucleolar pattern suggests systemic sclerosis. The pattern helps guide which specific antibody tests to order next.
Generally, repeating an ANA test is not recommended if a reliable result has been obtained. ANA titers can fluctuate but do not reliably track disease activity. Once a positive ANA has been established and specific antibodies identified, follow-up monitoring should focus on disease-specific markers (e.g., anti-dsDNA titers and complement levels for lupus) rather than re-checking the ANA.

Biomarcadores relacionados

Lectura relacionada

Referencias y enfoque de revisión

Las páginas del glosario de biomarcadores son explicaciones educativas y deben interpretarse junto con los rangos de referencia y comentarios proporcionados por tu laboratorio y tu profesional de salud. Para conocer nuestros estándares editoriales y proceso de revisión, consulta nuestra Política editorial y nuestro Proceso de revisión de contenido.

¿Quieres analizar tus niveles de ANA?

Sube tus resultados de laboratorio para recibir un análisis instantáneo con IA de todos tus biomarcadores.

Subir resultados de laboratorio →

Aviso médico: Esta información es solo educativa y no sustituye el consejo, diagnóstico ni tratamiento médico profesional. Los rangos de referencia pueden variar entre laboratorios. Consulta siempre a tu profesional sanitario para interpretar tus resultados concretos.

Aviso: SymptomGPT no es una herramienta de diagnóstico médico y no ofrece consejo médico. Consulta siempre a un profesional de la salud calificado. Si estás teniendo una emergencia médica, llama de inmediato al número de emergencias de tu zona.